Enzalutamide

Xtandi

Anti-Androgen Oral FDA/EMA Label

Half-life

5.8 days

Time to Peak

1 hr

Steady State

~29 days

Dose Range

80–160 mg

Frequency

Daily

Overview

Second-generation non-steroidal anti-androgen. Primarily used for metastatic castration-resistant prostate cancer. Rarely used in HRT due to cost and side effect profile. More potent than bicalutamide at the androgen receptor.

Mechanism of Action

Androgen receptor antagonist that also inhibits AR nuclear translocation and DNA binding. More complete AR blockade than first-generation NSAAs.

Dosing Information

Route	Dose Range	Half-life	Tmax	Frequency
Oral	80–160 mg	5.8 days	1 hr	Daily

Used in Regimens

Enzalutamide is not currently part of any catalog regimen.

Data Sources

FDA Label Xtandi (enzalutamide) FDA Prescribing Information

Related Tools

Medication Level Plotter

See blood level curves for this compound

Dose Calculator

Calculate reconstitution and draw volumes

Split Dose Calculator

Divide your weekly dose into multiple injections

Track Enzalutamide with Doseline

Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.

Join the waitlist

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.